Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicitas Thol

Showing results (71-80 of 126) with videos related to

Pageof 13
Sort By:
Blood|December 17, 2013
Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implicationsFelicitas Thol, Robin Bollin, Marten Gehlhaar, et al.
Annals of Hematology|April 11, 2012
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromesFelicitas Thol, Haiyang Yun, Ann-Kathrin Sonntag, et al.
Journal of Hematology & Oncology|August 16, 2023
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual diseaseJonas S Heitmann, Richard F Schlenk, Daniela Dörfel, et al.
Haematologica|July 20, 2023
Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemiaRabia Shahswar, Gernot Beutel, Razif Gabdoulline, et al.
Annals of Hematology|September 6, 2025
Comparison of prognostication by IPSS-M, IPSS-R and AIPSS-MDS in the context of limited availability of molecular data in daily clinical practiceFelicitas Schulz, Carolin Kellersmann, Beate Betz, et al.
Haematologica|January 13, 2018
Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndromeAniththa Thivakaran, Lacramioara Botezatu, Judith M Hönes, et al.
Annals of Hematology|May 20, 2019
Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivoNidhi Jyotsana, Amit Sharma, Anuhar Chaturvedi, et al.
Hemasphere|March 11, 2025
Cell-free DNA for detection and monitoring of extramedullary AML relapseHenri C Hupe, Clara P Wienecke, Stephan Bartels, et al.
Frontiers in Immunology|November 2, 2023
CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumorsAnna Christina Dragon, Luca Marie Beermann, Melina Umland, et al.
Leukemia|January 8, 2025
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agentsRabia Shahswar, Razif Gabdoulline, Katja Krueger, et al.
Pageof 13

Showing results (71-80 of 126) with videos related to

Sort By:
Pageof 13
Blood|December 17, 2013
Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implicationsFelicitas Thol, Robin Bollin, Marten Gehlhaar, et al.
Annals of Hematology|April 11, 2012
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromesFelicitas Thol, Haiyang Yun, Ann-Kathrin Sonntag, et al.
Journal of Hematology & Oncology|August 16, 2023
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual diseaseJonas S Heitmann, Richard F Schlenk, Daniela Dörfel, et al.
Haematologica|July 20, 2023
Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemiaRabia Shahswar, Gernot Beutel, Razif Gabdoulline, et al.
Annals of Hematology|September 6, 2025
Comparison of prognostication by IPSS-M, IPSS-R and AIPSS-MDS in the context of limited availability of molecular data in daily clinical practiceFelicitas Schulz, Carolin Kellersmann, Beate Betz, et al.
Haematologica|January 13, 2018
Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndromeAniththa Thivakaran, Lacramioara Botezatu, Judith M Hönes, et al.
Annals of Hematology|May 20, 2019
Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivoNidhi Jyotsana, Amit Sharma, Anuhar Chaturvedi, et al.
Hemasphere|March 11, 2025
Cell-free DNA for detection and monitoring of extramedullary AML relapseHenri C Hupe, Clara P Wienecke, Stephan Bartels, et al.
Frontiers in Immunology|November 2, 2023
CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumorsAnna Christina Dragon, Luca Marie Beermann, Melina Umland, et al.
Leukemia|January 8, 2025
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agentsRabia Shahswar, Razif Gabdoulline, Katja Krueger, et al.
Pageof 13